11 January 2019

In Alzheimers Research & Therapy Esther Karssemeijer and Roy Kessels from the departments of Geriatrics and Medical Psychology showed that a 12-week exergame and aerobic training improve psychomotor speed in people with dementia.

They performed a randomized controlled trial investigating the effect of exergame training and aerobic training on cognitive functioning in older adults with dementia. One hundred fifteen community-dwelling people with dementia (mean age 79.years) were trained 3 times a week during 12 weeks. Cognitive functioning was measured at baseline and after 12 weeks. A significant improvement in psychomotor speed was found in the aerobic and exergame groups compared to the active control group after 12-weeks, with a moderate effect size. This finding may be clinically relevant, as psychomotor speed is an important predictor for functional decline
No significant differences between the intervention and control groups were found for executive functioning, episodic memory and working memory.

In this study the authors also demonstrated that exergaming is a feasible  and positively rated exercise method for people with dementia, resulting in higher training adherence in the exergame group compared to the aerobic group (87.3 versus 81.1%). Accordingly, exergaming seems to be an effective method to engage people with dementia in physical exercise.
 

Related news items


Milk fat to attenuate obesity-related neurological co-morbidities

18 November 2021 The use of lipids to attenuate co-morbidities of obesity may sound paradoxical. However, it has shown to be particularly relevant in the fight against a less familiar co-morbidity of obesity, as it can induce alterations in white matter tracks, neuroinflammation and increases the risk of dementia. read more

Early stage biomarker for Alzheimer's disease

4 November 2021 Researchers from the translational metabolic lab and department of neurology, in collaboration with researchers from University of Barcelona, set out to research a new biomarker in cerebrospinal fluid called “neuroleukin” for Alzheimer's disease. read more

2.5 million euro for research on dementia Deltaplan Dementia

10 August 2017 The national funding programme Memorabel II awarded funding for six research projects and three partner projects. This will bolster research on dementia at Radboudumc and the Donders Institute. read more